1. Australia Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Cryosite Limited

Cryosite Limited

CTE.AX
Cryosite LimitedAU flagAustralian Securities Exchange
1.25
AUD
- -
- -
61.01MMarket Cap
Cryosite Limited
CTE.AX
(Australian Securities Exchange)

Recent

price

1.25

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.13
0.14
0.17
0.18
0.2
0.2
0.21
0.2
0.13
0.17
0.19
0.21
0.24
0.24
0.26
0.29
Revenue per Share
- -
0.01
0.02
0.03
0.01
0.01
0.01
- -
-0.03
-0.01
0.03
0.01
0.03
0.03
0.04
0.04
Basic EPS, GAAP
0.02
0.02
0.04
0.03
0.02
0.02
- -
0.03
- -
- -
-0.02
-0.01
-0.02
-0.01
-0.01
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
0.01
0.01
0.01
0.01
0.01
- -
- -
- -
- -
- -
0.01
0.01
0.02
Dividend per Share
0.09
0.1
0.11
0.13
0.13
0.07
0.07
0.07
0.04
-0.04
-0.01
0.01
0.04
0.06
0.03
0.05
Book Value per Share
0.09
0.1
0.12
0.13
0.13
0.07
0.06
0.06
0.04
-0.04
-0.01
0.01
0.04
0.06
0.03
0.05
Tangible Book Value per Share
47
47
47
47
47
47
47
47
47
47
47
47
49
49
49
49
Basic Weighted Avg Shares
6
6
8
8
9
10
10
10
6
8
9
10
12
12
13
14
Sales/Revenue/Turnover
-7.22
-6.41
2.66
3.99
-1.78
-3.11
-3.17
-8.57
-2.82
-0.24
18.74
10.6
16.09
12.77
16.29
17.68
Operating Margin (%)
- -
1
1
1
1
1
1
1
- -
- -
- -
1
1
1
1
1
Depreciation Expense
- -
- -
1
1
1
- -
- -
- -
-1
-1
1
1
1
1
2
2
Net Income, GAAP
63.93
- -
- -
- -
25.46
24.96
31.14
32.67
388.94
- -
16.16
41.76
24.5
10.54
11.79
25.33
Effective Tax Rate (%)
0.08
5.2
13.18
14.71
5.51
4.74
3.01
2.35
-21.15
-7.14
16.59
6.51
11.6
11.81
14.59
13.35
Profit Margin (%)
2
3
4
6
6
5
5
6
5
4
4
4
8
5
4
4
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
2
2
2
LT Debt
4
5
5
6
6
4
3
3
2
-2
- -
- -
2
3
1
2
Total Equity
-3.57
- -
4.06
- -
-1.96
-4.62
-6.33
-16.97
18.76
- -
-378.39
51.17
68.79
33.67
38.15
41.73
Return on Invested Capital (%)
0.23
- -
21.31
- -
8.56
9.93
9.05
6.9
-49.16
- -
-357.23
55.09
67.28
35.39
40.08
44.59
Return on Capital (%)
0.11
7.8
21.1
22.19
8.48
9.89
9.05
6.9
-49.16
- -
- -
- -
123.53
60.69
86.98
99
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-9.36%
45.54%
64.87%
Free Cash Flow
98.67%
15.16%
29.65%
Net Income, GAAP
-103.72%
17.87%
2.39%
Sales/Revenue/Turnover
5.78%
9.76%
11.93%
Total Cash Common Dividend
- -
- -
33.33%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
12
2024
- -
- -
- -
- -
13
2025
- -
- -
- -
- -
14

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.03
2024
- -
- -
- -
- -
0.04
2025
- -
- -
- -
- -
0.04

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.01
2024
- -
- -
- -
- -
0.01
2025
- -
- -
- -
- -
0.02
Similar Companies
NanoRepro AG (NNGRF)
Veracyte, Inc. (VCYT)
ICON Public Limited Company (ICLR)
Twist Bioscience Corporation (TWST)
China Biotech Services Holdings Limited (8037.HK)
Tecan Group AG (TCHBF)
Business
Cryosite Limited Cryosite Limited (ASX: CTE) provides outsourced clinical trials logistic services and biological storage solutions in Australia. The company operates through two primary segments: Clinical Trials and Biological Services Logistics, which offers specialist temperature-controlled storage including ambient, cold, frozen, ultra-frozen, and liquid nitrogen options; sourcing, labelling, status management, secondary packaging, scheduled drug distribution, destruction, returns, and depot services for biological and cell gene therapies; and Cord Blood and Tissues Storage, which delivers long-term storage for cord blood and tissue samples. Cryosite Limited serves the research, medical, pharmaceutical, and biotechnology industries, managing the full clinical trial supply chain from importation and receipt of temperature-sensitive products to distribution and reverse logistics. Established in 2000 and headquartered at 13a Ferndell Street, South Granville, New South Wales, the company maintains operations focused on the Australian market with facilities equipped for 24-hour temperature monitoring and compliance with Therapeutic Goods Administration standards. In October 2025, Cryosite Limited entered a binding contract to acquire a strategic freehold warehouse facility at 100 Adderley Street West, Auburn, NSW, for $9.50 million, adding over 100% usable warehousing capacity to address growing client demand for investigational therapies and biologicals storage; the transaction, funded by cash reserves and a new debt facility from a Big Four Australian bank, supports expansion into medical device storage, pallet storage, and potential short-term leasing while enhancing operational resilience and business continuity through dual-site compliance.